Literature DB >> 33419766

Cbl-b Is Upregulated and Plays a Negative Role in Activated Human NK Cells.

Ting Lu1, Li Chen1, Anthony G Mansour1, Melissa J Yu1, Noah Brooks1, Kun-Yu Teng1, Zhenlong Li1, Jianying Zhang2, Tasha Barr1, Jianhua Yu1,3,4,5, Michael A Caligiuri6,3,4,5.   

Abstract

The E3 ubiquitin ligase Cbl-b has been characterized as an intracellular checkpoint in T cells; however, the function of Cbl-b in primary human NK cells, an innate immune anti-tumor effector cell, is not well defined. In this study, we show that the expression of Cbl-b is significantly upregulated in primary human NK cells activated by IL-15, IL-2, and the human NK cell-sensitive tumor cell line K562 that lacks MHC class I expression. Pretreatment with JAK or AKT inhibitors prior to IL-15 stimulation reversed Cbl-b upregulation. Downregulation of Cbl-b resulted in significant increases in granzyme B and perforin expression, IFN-γ production, and cytotoxic activity against tumor cells. Collectively, we demonstrate upregulation of Cbl-b and its inhibitory effects in IL-15/IL-2/K562-activated human NK cells, suggesting that Cbl-b plays a negative feedback role in human NK cells.
Copyright © 2021 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33419766      PMCID: PMC8184061          DOI: 10.4049/jimmunol.2000177

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.426


  70 in total

1.  Cbl Ubiquitin Ligases Control B Cell Exit from the Germinal-Center Reaction.

Authors:  Xin Li; Adeline Gadzinsky; Liying Gong; Haijun Tong; Virginie Calderon; Yue Li; Daisuke Kitamura; Ulf Klein; Wallace Y Langdon; Fajian Hou; Yong-Rui Zou; Hua Gu
Journal:  Immunity       Date:  2018-03-20       Impact factor: 31.745

2.  Multiple natural killer cell-activating signals are inhibited by major histocompatibility complex class I expression in target cells.

Authors:  I Correa; L Corral; D H Raulet
Journal:  Eur J Immunol       Date:  1994-06       Impact factor: 5.532

3.  Increased Tim-3 expression in peripheral NK cells predicts a poorer prognosis and Tim-3 blockade improves NK cell-mediated cytotoxicity in human lung adenocarcinoma.

Authors:  Liyun Xu; Yanyan Huang; Linlin Tan; Wei Yu; Dongdong Chen; ChangChang Lu; Jianying He; Guoqing Wu; Xiaoguang Liu; Yongkui Zhang
Journal:  Int Immunopharmacol       Date:  2015-10-01       Impact factor: 4.932

4.  A potential role for interleukin-15 in the regulation of human natural killer cell survival.

Authors:  W E Carson; T A Fehniger; S Haldar; K Eckhert; M J Lindemann; C F Lai; C M Croce; H Baumann; M A Caligiuri
Journal:  J Clin Invest       Date:  1997-03-01       Impact factor: 14.808

5.  New role for Shc in activation of the phosphatidylinositol 3-kinase/Akt pathway.

Authors:  H Gu; H Maeda; J J Moon; J D Lord; M Yoakim; B H Nelson; B G Neel
Journal:  Mol Cell Biol       Date:  2000-10       Impact factor: 4.272

6.  Negative regulation of CD40-mediated B cell responses by E3 ubiquitin ligase Casitas-B-lineage lymphoma protein-B.

Authors:  Guilin Qiao; Minxiang Lei; Zhenping Li; Yonglian Sun; Andrew Minto; Yang-Xin Fu; Haiyan Ying; Richard J Quigg; Jian Zhang
Journal:  J Immunol       Date:  2007-10-01       Impact factor: 5.422

7.  Interleukin-2-induced tyrosine phosphorylation of Shc proteins correlates with factor-dependent T cell proliferation.

Authors:  X Zhu; K L Suen; M Barbacid; J B Bolen; J Fargnoli
Journal:  J Biol Chem       Date:  1994-02-25       Impact factor: 5.157

8.  AZD1480: a phase I study of a novel JAK2 inhibitor in solid tumors.

Authors:  Elizabeth R Plimack; Patricia M Lorusso; Patricia McCoon; Weifeng Tang; Annetta D Krebs; Gregory Curt; S Gail Eckhardt
Journal:  Oncologist       Date:  2013-07-11

Review 9.  Targeting NK-cell checkpoints for cancer immunotherapy.

Authors:  Aura Muntasell; Maria C Ochoa; Luna Cordeiro; Pedro Berraondo; Ascension López-Díaz de Cerio; Mariona Cabo; Miguel López-Botet; Ignacio Melero
Journal:  Curr Opin Immunol       Date:  2017-02-23       Impact factor: 7.486

Review 10.  Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells.

Authors:  Nayoung Kim; Hun Sik Kim
Journal:  Front Immunol       Date:  2018-09-10       Impact factor: 7.561

View more
  2 in total

1.  CBLB ablation with CRISPR/Cas9 enhances cytotoxicity of human placental stem cell-derived NK cells for cancer immunotherapy.

Authors:  Xuan Guo; Tanel Mahlakõiv; Qian Ye; Srinivas Somanchi; Shuyang He; Hemlata Rana; Andrea DiFiglia; Joseph Gleason; William van der Touw; Robert Hariri; Xiaokui Zhang
Journal:  J Immunother Cancer       Date:  2021-03       Impact factor: 13.751

2.  Hijacking TYRO3 from Tumor Cells via Trogocytosis Enhances NK-cell Effector Functions and Proliferation.

Authors:  Ting Lu; Rui Ma; Zhenlong Li; Anthony G Mansour; Kun-Yu Teng; Li Chen; Jianying Zhang; Tasha Barr; Michael A Caligiuri; Jianhua Yu
Journal:  Cancer Immunol Res       Date:  2021-07-29       Impact factor: 12.020

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.